|View printer-friendly version|
|CytomX Therapeutics Appoints Charles S. Fuchs, M.D., MPH to Board of Directors|
“Dr. Fuchs’ appointment to the CytomX Board reflects the continued progression of the organization as a clinical stage, oncology-focused company developing novel, high potential medicines for people with cancer,” said Dr.
Dr. Fuchs is the Richard Sackler and Jonathan Sackler Professor of Medicine, Director of the
“We are delighted to welcome Dr. Fuchs to our Board as we continue to advance our pipeline of Probody therapeutics for the treatment of cancer,” said
CytomX Therapeutics Forward-Looking Statements